Summary

Balaji Amines Limited demonstrated a resilient performance for the quarter and financial year ended March 31, 2026. Consolidated revenue for Q4FY26 increased by 11.6% year-on-year to ₹ 403 crore, while consolidated EBITDA grew significantly by 50.0% to ₹ 102 crore, with margins expanding to 25%. Net Profit for the quarter saw a strong surge of 62.5% to ₹ 65 crore. For the full fiscal year, consolidated revenue stood at ₹ 1,454 crore and PAT at ₹ 169 crore, reflecting steady growth. The company is actively pursuing growth through new project commissions and a substantial ₹ 750 crore expansion for its subsidiary, Balaji Speciality Chemicals.

Key Highlights

1. 1

   Consolidated revenue from operations for Q4FY26 stood at ₹ 403 crore, marking an 11.6% year-on-year increase from ₹ 361 crore in Q4FY25.

2. 2

   Consolidated EBITDA for Q4FY26 significantly rose by 50.0% year-on-year to ₹ 102 crore, with margins improving to 25% compared to 19% in Q4FY25.

3. 3

   Consolidated Net Profit (PAT) for Q4FY26 surged by 62.5% year-on-year to ₹ 65 crore, up from ₹ 40 crore in the prior year quarter.

4. 4

   For the full financial year FY26, consolidated revenue reached ₹ 1,454 crore, a 1.7% increase from ₹ 1,430 crore in FY25, while consolidated PAT grew 6.3% to ₹ 169 crore.

5. 5

   Total consolidated sales volumes for Q4FY26 were 27,341 MT, representing a 5.7% increase compared to 25,872 MT in Q4FY25.

6. 6

   The company is advancing several new projects, including a DME Plant, an N-Methyl Morpholine (NMM) plant, and an Acetonitrile plant, all expected to be commissioned during FY 2026-27.

7. 7

   Balaji Speciality Chemicals Limited, a subsidiary, was granted Mega Project status for a proposed ₹ 750 crore expansion, encompassing products like Hydrogen Cyanide and Sodium Cyanide.